Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: If only I'd held who wrote (35276)	5/7/1999 9:51:00 AM
From: kennny	Respond to of 122087

I'm in..will stay in..Spoke to OBGYN friend yesterday...Said there are several new tests on the market..didn't hear of this one yet...sounded good to him and he is going to check it out... I think the bottom line is that we will have to wait for the word to get out.

To: If only I'd held who wrote (35276)	5/11/1999 9:37:00 AM
From: Rob29	Read Replies (2) \| Respond to of 122087

DIGE news out this morning. biz.yahoo.com Tuesday May 11, 8:17 am Eastern Time Company Press Release SOURCE: Digene Corporation Digene Corporation Announces Marketing and Distribution Alliance With Abbott Laboratories BELTSVILLE, Md., May 11 /PRNewswire/ -- Digene Corporation (Nasdaq: DIGE - news) today announced it has formed an exclusive marketing alliance with Abbott Laboratories, (NYSE: ABT - news) for Digene's Women's Health and Blood Virus testing products. The agreement calls for Abbott to assume sales and marketing responsibility for all of Digene's Hybrid Capture® products in Europe, Middle East and Africa and for Digene's Hybrid Capture II chlamydia and gonorrhea tests in the United States. The agreement replaces previous agreements between Digene and International Murex Technologies Corporation, a company acquired by Abbott in 1998. ''Abbott has a strong commitment to probe diagnostics,'' said Thomas D. Brown, Abbott Senior Vice President, Diagnostic Operation, ''Digene's Hybrid Capture technology compliments our established LCx probe diagnostic portfolio.'' ''Expanding our relationship with Abbott is a major milestone in our efforts to commercialize our Hybrid Capture technology,'' stated Evan Jones, President and CEO, Digene. ''In Europe, we expect to accelerate our efforts to establish Human Papillomavirus (HPV) testing as a primary cervical cancer screening test. In the United States, we plan to work with Abbott to launch our fully automated DNA probe tests for chlamydia and gonorrhea. Abbott's marketing expertise in testing for blood viruses is expected to further develop Digene's strong position in testing for hepatitis B DNA.'' Preliminary results of recent clinical trials indicate that cervical cancer screening using HPV testing is a more sensitive method of detecting cervical cancer precursors than traditional Pap smear screening. There are estimated to be 30 to 40 million Pap smear screening tests each year in Europe. Digene's Hybrid Capture technology uses signal amplification to combine the accuracy of nucleic acid probe diagnostics with the benefits of the antibody-based, or immunodiagnostic systems routinely used by clinical laboratories today. Hybrid Capture II products use industry standard, 96-well microtitier plates to achieve new levels of performance and convenience. Digene Corporation develops, manufactures and markets DNA and RNA tests for the detection, screening and monitoring of human diseases. Digene's products are designed to help improve clinical outcomes and reduce the overall cost of disease management. Digene's lead product, the Hybrid Capture II HPV Test, aids physicians in identifying women who are most at risk of having or developing cervical disease and cervical cancer. The Digene HPV Test is used in the U.S. as an adjunct to the Pap smear for cervical cancer screening and is being marketed in selected countries as a primary cervical cancer screen either in conjunction with or separate from the Pap smear. This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may vary materially from expectations. Such factors include the failure to obtain regulatory approval to market, and the failure to obtain reimbursement for, Digene's Human Papillomavirus, chlamydia, gonorrhea and hepatitis B tests in the territories covered by the Agreement, lack of significant acceptance of the tests by the medical community and risks inherent in international transactions. For other factors, reference is made to the discussion in the Company's annual and quarterly reports filed with the Securities and Exchange Commission. SOURCE: Digene Corporation More Quotes and News: Abbott Laboratories (NYSE:ABT - news) Digene Corp (Nasdaq:DIGE - news) Related News Categories: biotech, medical/pharmaceutical